Enbrel vs. Cosentyx

• Are Enbrel and Cosentyx the Same Thing?
• What Are Possible Side Effects of Enbrel?
• What Are Possible Side Effects of Cosentyx?
• What is Enbrel?
• What is Cosentyx?
• What Drugs Interact with Enbrel?
• What Drugs Interact with Cosentyx?
• How Should Enbrel Be Taken?
• How Should Cosentyx Be Taken?

Enbrel (etanercept) and Cosentyx (secukinumab) are used to treat plaque psoriasis.

Enbrel is also used to treat certain autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.

Enbrel and Cosentyx belong to different drug classes. Enbrel is a tumor necrosis factor (TNF) inhibitor and Cosentyx is a human interleukin-17A antagonist.

Side effects of Enbrel and Cosentyx that are similar include diarrhea.

Side effects of Enbrel that are different from Cosentyx include mild nausea, vomiting, stomach pain, headache, redness or discomfort at the injection site, heartburn, weight changes, cold symptoms (cough, runny nose), or weakness.

Side effects of Cosentyx that are different from Enbrel include sore throat and nose, upper respiratory tract infection, sinus infection (sinusisits), stuffy or runny nose, oral herpes, hives, athlete's foot, tonsillitis, oral thrush, impetigo, inflammatory bowel disease, ear infection, eye infection or inflammation (conjunctivitis), increased liver transaminases, and low white blood cell count (neutropenia).

Enbrel may interact with anakinra, cyclophosphamide, sulfasalazine, or drugs that weaken your immune system (such as cancer medicine or steroids).

Cosentyx may interact with warfarin, cyclosporine, or "live" vaccines.

Common side effects of Enbrel include:

• Mild nausea
• Vomiting
• Diarrhea
• Stomach pain
• Headache
• Redness or discomfort at the injection site
• Heartburn
• Weight changes
• Cold symptoms (cough, runny nose)
• Weakness

Serious side effects include:

• Seizures
• Bruising
• Bleeding
• Skin changes (rash, pustules, blisters, patchy skin color, red spots, or a butterfly-shaped rash over cheeks and nose)
• Swelling
• Difficulty breathing or swallowing
• Numbness and tingling, burning pain
• Vision changes
• Dizziness
• Signs of infection (fever, chills, sore throat, body aches, confusion, neck stiffness, flu symptoms, itching, swelling, warmth, redness, or oozing),
• Rapid weight gain
• Chest pain
• Ongoing cough
• Coughing up mucus or blood
• Black, bloody, or tarry stools
• Changes in mood or personality (in children)
• Joint pain or swelling with fever, swollen glands, muscle aches, chest pain, unusual thoughts or behavior, and/or seizures (convulsions)

Common side effects of Cosentyx include:

• sore throat and nose,
• diarrhea,
• upper respiratory tract infection,
• sinus infection (sinusisits),
• stuffy or runny nose,
• oral herpes,
• hives,
• athlete's foot,
• tonsillitis,
• oral thrush,
• impetigo,
• inflammatory bowel disease,
• ear infection,
• eye infection or inflammation (conjunctivitis),
• increased liver transaminases, and
• low white blood cell count (neutropenia).

Enbrel (etanercept) is a tumor necrosis factor inhibitor used to treat certain autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and plaque psoriasis.

Cosentyx (secukinumab) for Injection is a human interleukin-17A antagonist used to treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Enbrel may interact with anakinra, cyclophosphamide, sulfasalazine, or drugs that weaken your immune system (such as cancer medicine or steroids). Tell your doctor all medications and supplements you use.

Cosentyx may interact with warfarin, cyclosporine, or "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Cosentyx. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Enbrel is available in three preparations; 0.98 mL of a 50 mg/mL solution of etanercept, 0.51 mL of a 50 mg/mL solution of etanercept and 25 mg etanercept. All are used for injection; only the 25 mg strength is available in a multiuse vial, the others are available in a prefilled syringe. Starting dose is often 50 mg injected twice a week in adults and 0.8 mg per Kg in pediatric patients weighing less than 63 Kg. Other doses may be used.

The recommended dose of Cosentyx is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg.